Tibet Weixinkang Medicine Co Ltd (603676) - Total Assets
Based on the latest financial reports, Tibet Weixinkang Medicine Co Ltd (603676) holds total assets worth CN¥1.91 Billion CNY (≈ $279.41 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See what is Tibet Weixinkang Medicine Co Ltd's book value for net asset value and shareholders' equity analysis.
Tibet Weixinkang Medicine Co Ltd - Total Assets Trend (2013–2024)
This chart illustrates how Tibet Weixinkang Medicine Co Ltd's total assets have evolved over time, based on quarterly financial data.
Tibet Weixinkang Medicine Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Tibet Weixinkang Medicine Co Ltd's total assets of CN¥1.91 Billion consist of 71.0% current assets and 29.0% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 11.7% |
| Accounts Receivable | CN¥174.22 Million | 9.4% |
| Inventory | CN¥41.96 Million | 2.3% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥30.43 Million | 1.6% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Tibet Weixinkang Medicine Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Tibet Weixinkang Medicine Co Ltd (603676) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tibet Weixinkang Medicine Co Ltd's current assets represent 71.0% of total assets in 2024, an increase from 52.2% in 2013.
- Cash Position: Cash and equivalents constituted 11.7% of total assets in 2024, down from 32.3% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 2.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 9.4% of total assets.
Tibet Weixinkang Medicine Co Ltd Competitors by Total Assets
Key competitors of Tibet Weixinkang Medicine Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Zhejiang Huahai Pharmaceutical Co Ltd
SHG:600521
|
China | CN¥21.15 Billion |
|
Emcure Pharmaceuticals Ltd
NSE:EMCURE
|
India | Rs93.93 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538
|
China | CN¥4.75 Billion |
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr67.43 Billion |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
|
China | CN¥3.02 Billion |
Tibet Weixinkang Medicine Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.07 | 3.36 | 2.43 |
| Quick Ratio | 3.93 | 3.27 | 2.37 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.01 Billion | CN¥960.10 Million | CN¥526.10 Million |
Tibet Weixinkang Medicine Co Ltd - Advanced Valuation Insights
This section examines the relationship between Tibet Weixinkang Medicine Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.17 |
| Latest Market Cap to Assets Ratio | 0.37 |
| Asset Growth Rate (YoY) | 4.3% |
| Total Assets | CN¥1.85 Billion |
| Market Capitalization | $677.53 Million USD |
Valuation Analysis
Below Book Valuation: The market values Tibet Weixinkang Medicine Co Ltd's assets below their book value (0.37x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Tibet Weixinkang Medicine Co Ltd's assets grew by 4.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Tibet Weixinkang Medicine Co Ltd (2013–2024)
The table below shows the annual total assets of Tibet Weixinkang Medicine Co Ltd from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.85 Billion ≈ $271.25 Million |
+4.32% |
| 2023-12-31 | CN¥1.78 Billion ≈ $260.02 Million |
+6.74% |
| 2022-12-31 | CN¥1.66 Billion ≈ $243.60 Million |
+11.31% |
| 2021-12-31 | CN¥1.50 Billion ≈ $218.85 Million |
+9.96% |
| 2020-12-31 | CN¥1.36 Billion ≈ $199.02 Million |
+4.25% |
| 2019-12-31 | CN¥1.30 Billion ≈ $190.91 Million |
+5.64% |
| 2018-12-31 | CN¥1.23 Billion ≈ $180.72 Million |
+21.48% |
| 2017-12-31 | CN¥1.02 Billion ≈ $148.76 Million |
+84.05% |
| 2016-12-31 | CN¥552.36 Million ≈ $80.83 Million |
+8.57% |
| 2015-12-31 | CN¥508.75 Million ≈ $74.45 Million |
+40.01% |
| 2014-12-31 | CN¥363.37 Million ≈ $53.17 Million |
+17.48% |
| 2013-12-31 | CN¥309.30 Million ≈ $45.26 Million |
-- |
About Tibet Weixinkang Medicine Co Ltd
Tibet Weixinkang Medicine Co., Ltd. engages in the research and development, production, and sale of chemical drugs and their bulk drugs in China. The company offers parenteral nutrition vitamins; electrolyte supplements; intravenous iron, trace, electrolytes, and amino acids supplements; antibiotics; acetylcysteine solution for inhalation; medicine for liver diseases; and other special fields. I… Read more